UK markets closed

Aldeyra Therapeutics, Inc. (ALDX)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
3.9300-0.0100 (-0.25%)
At close: 04:00PM EDT
3.8400 -0.09 (-2.29%)
After hours: 04:34PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 233.50M
Enterprise value 106.33M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.95
Enterprise value/revenue N/A
Enterprise value/EBITDA -3.02

Trading information

Stock price history

Beta (5Y monthly) 1.52
52-week change 3-61.01%
S&P500 52-week change 322.36%
52-week high 311.9700
52-week low 31.4200
50-day moving average 33.6434
200-day moving average 34.4456

Share statistics

Avg vol (3-month) 3588.01k
Avg vol (10-day) 3484.62k
Shares outstanding 559.41M
Implied shares outstanding 659.41M
Float 842.78M
% held by insiders 11.99%
% held by institutions 161.60%
Shares short (15 Apr 2024) 42.36M
Short ratio (15 Apr 2024) 43.08
Short % of float (15 Apr 2024) 44.79%
Short % of shares outstanding (15 Apr 2024) 43.97%
Shares short (prior month 15 Mar 2024) 41.83M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-16.23%
Return on equity (ttm)-27.73%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -42.53M
Net income avi to common (ttm)-37.54M
Diluted EPS (ttm)-0.6400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)142.82M
Total cash per share (mrq)2.42
Total debt (mrq)15.66M
Total debt/equity (mrq)13.07%
Current ratio (mrq)6.64
Book value per share (mrq)2.02

Cash flow statement

Operating cash flow (ttm)-30.33M
Levered free cash flow (ttm)-27.62M